Winners and Losers In Democrat’s Mega Social Spending Package

Industry almost certain to avoid its worst pricing reform fears, but some post-exclusivity drugs may still be subject to negotiations under the most recent iteration of Build Back Better. Meanwhile, rare disease development incentives get cut and new funding is doled out for FDA.